Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New Taiyo Yakuhin May Consider IPO: President Aratani
June 14, 2010
- Miraka HD: Sales Up 2.6% to ¥149,074 Mil.
June 14, 2010
- CMIC: Half-Year Sales Up 12.7% to ¥16 Bil.
June 14, 2010
- Nihon Chouzai to Open 30 Pharmacies Downtown
June 14, 2010
- Takara's Technology Supports Bio Research in Japan: President Ohmiya
June 14, 2010
- Incentives for Use of Generics Boost Business of JGA Member Companies
June 7, 2010
- Astellas Aims at Sales of ¥1,100 Bil. In FY2014
June 7, 2010
- Meiji Seika: Pharm. Business Driven by Generics
June 7, 2010
- Women Receives Cervarix at 31.4 of Age on Average in Japan: GSK
June 7, 2010
- Teijin Pharma to Increase No. of MRs to Market TMX-67
June 7, 2010
- Zeria Aims at Overseas Sales Ratio of >25%: President Ibe
June 7, 2010
- Major New Entrants in Generics Market, Emergence of AGs
June 7, 2010
- Takeda Aims at Top Share for DPP-4 Inhibitors with Nesina
June 7, 2010
- Asahi Kasei Pharma: Sales Down 8.2% to ¥56.0 Bil.
June 7, 2010
- Revlimid, Torisel Recommended for Approval
June 7, 2010
- Mark Smith Appointed President of Merck Serono in Japan
June 7, 2010
- Yakult: Campto Patent Expiration Hits Pharm. Business
June 7, 2010
- Industry Should Generate Visible Benefits of New Premium System: Dr Suzuki of JMA
June 7, 2010
- Ethical Drugs' Sales Up 4.7% in FY2009: Crecon
June 7, 2010
- Fuso: Pharm. Sales Up 1.5% Driven by Dialysis-Related Products
June 7, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…